DHR Stock Danaher Corporation
US · NYSELast in our picks 2026-10-26 — not in the current list; analysis below is from that screen
Life-science recovery and AI-driven diagnostics create attractive cyclical and structural upside.
Future value: $258.86 (+12.30%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Improving research spending and laboratory automation outlook.
- ▸Above 50-day MA (+6.65%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (85% of range) — strength
Is DHR a buy right now?
Trend: DHR is trading above the 50-day average (+6.65%), RSI 35 — neutral momentum, with a 3-month return of +17.30%.
Valuation & quality: Danaher Corporation trades on a trailing P/E of 38.6, forward P/E 25.0, PEG 1.31, price-to-book 3.06; fundamentals show net margin 16.9%, return on equity 8.2%, revenue growth 8.3% year on year.
Analyst consensus: 21 analysts have a mean 12-month price target of $259.90 (+11.6% vs the last close; range $220.00 – $310.00), consensus rating “strong buy”.
Income: trailing dividend yield 0.69%.
Our screen: STRONG BUY (score 4) — Life-science recovery and AI-driven diagnostics create attractive cyclical and structural upside.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -10.00% | -5.60% | +2.10% | +4.30% | +2.40% | +9.50% | +3.70% | +4.00% |
Fundamentals
Analyst price target
Technical signals
About Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments.
Sector: Healthcare · Industry: Diagnostics & Research · United States · 58,000 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.